Cities for Better Health Childhood Obesity Prevention Initiative

NCT06855563 · tracked via the Priya Life Science Canada tracker

Sponsor

Novo Nordisk A/S

Phase

Not applicable

Started

2025-04-30

Last updated

2026-09-16

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

Community-based intervention packages

Community-based intervention packages: Community-based intervention packages * Intervention packages are expected to consist of multiple specific activities tailored to the local context. All intervention packages will be designed to be (i) multi-level (i.e. targeting at least two of individual, external and structural environments), (ii) multi-component (i.e. targeting both healthy diet and physical activity), (iii) co-created with local communities in which they are implemented and (iv) health equity oriented in terms of both access and improvement. The exact package of interventions will differ by country and is expected to evolve pragmatically over time. * The intervention group in each country will be made up of (children in) neighbourhoods where intervention packages are implemented.

Study summary

This research project is part of the 'Cities for Better Health Childhood Obesity Prevention Initiative' (CBH COPI). The objective of the CBH COPI initiative is to develop, implement, and evaluate the effectiveness of a package of prevention interventions in five cities to promote healthy eating, physical activity, a positive health-related quality of life, and a reduction in rates living with overweight or obesity among children aged 6-13 years in six cities across Australia, Brazil, Canada, Japan, South Africa and Spain.

The primary research objective of CBH COPI is to estimate the impact of the intervention packages on the average BMI of the target population of children across the participating countries, at one-year and two-year follow-ups. The secondary research objective is to estimate the impact of the intervention packages on average health-related quality of life (HRQoL) at the same time points. Exploratory aims include estimating the impact of the packages on behaviours related to physical activity and diet.

Eligibility

Sex

ALL

Min age

6 Years

Max age

13 Years

Healthy volunteers

To be eligible to be involved in data collection, children must attend the 'clusters' (schools) that are part of the study. In each cluster, country evaluation teams will try to ensure that the sample of children selected for data collection is representative of the total population in that cluster (e.g. the full list of students ages 6-13 who go to that school) - in particular, with respect to age and sex. All countries will also use the inclusion and exclusion criteria below for children in the study: Inclusion Criteria: * Informed consent obtained by the child's parent or legal guardian before any study-related activities (where study-related activities are defined as any procedure related to recording of data according to the protocol). The specific consent form and procedures for obtaining consent will be outlined by the local project partner. * Aged 6-13 years (both 6 and 13 allowed) at the time of signing consent. Deviations from or exceptions to this procedure must be agreed between the research team in the relevant country and the GIP, and are subject to the relevant local ethical amendment procedure. The exception must be due to a scientifically sound rationale and must further consider the following guiding principles: "it must be measurable, it must have marginal utility, it must be meaningful (i.e. linked to the ultimate impact and the primary and/or secondary objective)". Exclusion Criteria: \- Children will be excluded from the study if their parent(s) do not provide fully informed consent for their data to be collected, if during the measurement day they do not agree to participate, or if the child's parent(s) or legal guardian(s) withdraw their consent for their child participating in the research at any point in line with processes described in local informed consent forms.

Primary outcome measure(s)

Body mass index z-score (BMI-z) adjusted for age and sex — At baseline, 1st follow-up (10-12 months) and 2nd follow-up (20-24 months)
z-score

Trial sites (6)

Facility	City	Region
Novo Nordisk Investigational Site	Logan	Australia
Novo Nordisk Investigational Site	Campinas	Brazil
Novo Nordisk Investigational Site	Mississauga	Canada
Novo Nordisk Investigational Site	Chiba	Japan
Novo Nordisk Investigational Site	Johannesburg	South Africa
Novo Nordisk Investigational Site	Madrid	Spain

More Novo Nordisk A/S trials in Canada

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity Active, not recruiting

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels Active, not recruiting

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity Recruiting

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) Active, not recruiting

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors Active, not recruiting

Other trials for the same condition

BariaPSY: the Data Bank Recruiting

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity Active, not recruiting

Magnetic Gastro-Ileal or Gastro-Jejunal Diversion Study ("MGI/MGJ Study") Active, not recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Recruiting

Digital Preparation for Bariatric Surgery: Feasability Pilot Trial Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06855563 on ClinicalTrials.gov ↗ ← All trials in Canada